The Montreal Heart Institute, in Montreal, Quebec, is a specialty hospital dedicated to the development of cardiology, which is affiliated with the Université de Montréal.

There are 153 beds in Institut de Cardiologie de Montreal.

During the past decade, Institut de Cardiologie de Montreal conducted 27 clinical trials. In the 10-year time frame, 27 clinical trials started and 12 clinical trials were completed, i.e. on average, 44.4% percent of trials that started reached the finish line to date. In the past 5 years, 14 clinical trials started and 7 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institut de Cardiologie de Montreal" #1 sponsor was "Abbott Medical Devices" with 18 trials, followed by "Boston Scientific Corporation" with 5 trials sponsored, "Advanz Pharma" with 3 trials sponsored, "DalCor Pharmaceuticals" with 2 trials sponsored and "Astellas Pharma Europe Ltd." with 2 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 21 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institut de Cardiologie de Montreal" #1 collaborator was "The Montreal Health Innovations Coordinating Center (MHICC)" with 3 trials as a collaborator, "Astellas Pharma US, Inc." with 2 trials as a collaborator, "Canadian Institutes of Health Research (CIHR)" with 2 trials as a collaborator, "Abbott" with 1 trials as a collaborator and "Abbott Medical Devices" with 1 trials as a collaborator. Other collaborators include 31 different institutions and companies that were collaborators in the rest 41 trials.

According to Clinical.Site data, the most researched conditions in "Institut de Cardiologie de Montreal" are "Atrial Fibrillation" (4 trials), "Heart Failure" (4 trials), "Bradycardia" (3 trials), "Aortic Valve Disease" (2 trials) and "Aortic Valve Stenosis" (2 trials). Many other conditions were trialed in "Institut de Cardiologie de Montreal" in a lesser frequency.

Most popular intervention types in "Institut de Cardiologie de Montreal" are "Device" (26 trials), "Drug" (16 trials), "Procedure" (4 trials), "Biological" (1 trials) and "Dietary Supplement" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (8 trials), "Vernakalant Injection 20 mg/mL" (2 trials), "1-Methylnicotinamide (1-MNA)" (1 trials), "ACURATE Prime™ Transfemoral TAVR System XL" (1 trials) and "ACURATE neo2™ Transfemoral TAVR System" (1 trials). Other intervention names were less common.

The vast majority of trials in "Institut de Cardiologie de Montreal" are 45 trials for "All" genders.

Currently, there are NaN active trials in "Institut de Cardiologie de Montreal". undefined are not yet recruiting, 9 are recruiting, 10 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 19 completed trials in Institut de Cardiologie de Montreal, 1 suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Institut de Cardiologie de Montreal, 0 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 18 trials that are defined as “Not Applicable".